D6M Stock Overview
A molecular diagnostics company, engages in developing and commercializing point of need diagnostics platform for infectious diseases, genotyping, pathogen detection, and other indications.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 4/6 |
Dividends | 0/6 |
genedrive plc Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | UK£0.0075 |
52 Week High | UK£0.11 |
52 Week Low | UK£0.002 |
Beta | -0.038 |
11 Month Change | -48.28% |
3 Month Change | 66.67% |
1 Year Change | -84.85% |
33 Year Change | -96.65% |
5 Year Change | n/a |
Change since IPO | -99.56% |
Recent News & Updates
Recent updates
Shareholder Returns
D6M | DE Life Sciences | DE Market | |
---|---|---|---|
7D | -6.3% | -2.6% | -1.0% |
1Y | -84.8% | 0.9% | 12.8% |
Return vs Industry: D6M underperformed the German Life Sciences industry which returned 0.9% over the past year.
Return vs Market: D6M underperformed the German Market which returned 12.8% over the past year.
Price Volatility
D6M volatility | |
---|---|
D6M Average Weekly Movement | 47.7% |
Life Sciences Industry Average Movement | 6.1% |
Market Average Movement | 4.9% |
10% most volatile stocks in DE Market | 11.1% |
10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: D6M's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: D6M's weekly volatility has decreased from 81% to 48% over the past year, but is still higher than 75% of German stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2000 | 43 | Gino Miele | www.genedriveplc.com |
genedrive plc, a molecular diagnostics company, engages in developing and commercializing point of need diagnostics platform for infectious diseases, genotyping, pathogen detection, and other indications. The company provides Genedrive system, a rapid thermocycler and signal detection system and semi- automated system used for qualitative in vitro molecular diagnostic tests; and Genedrive CYP2C19 ID Kit, a point-of-care test for rapid CYP2C19 genotyping in time-critical emergency care settings. It also offers Genedrive MT-RNR1-ID Kit, a rapid genetic test in an emergency neonatal care setting; and tests for the detection of Antibiotic Induced Hearing Loss in neonates, confirmation of HCV infection prior to drug administration, pathogen detection of biological military threats and a point-of-care for COVID-19 detection system for use in areas, such as healthcare, workplace screening, travel requirements, and confirmation of antigen tests.
genedrive plc Fundamentals Summary
D6M fundamental statistics | |
---|---|
Market cap | €11.83m |
Earnings (TTM) | -€5.97m |
Revenue (TTM) | €324.64k |
36.4x
P/S Ratio-2.0x
P/E RatioIs D6M overvalued?
See Fair Value and valuation analysisEarnings & Revenue
D6M income statement (TTM) | |
---|---|
Revenue | UK£272.00k |
Cost of Revenue | UK£3.81m |
Gross Profit | -UK£3.54m |
Other Expenses | UK£1.46m |
Earnings | -UK£5.00m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -0.0092 |
Gross Margin | -1,301.47% |
Net Profit Margin | -1,837.50% |
Debt/Equity Ratio | 0% |
How did D6M perform over the long term?
See historical performance and comparison